Press Releases

Date Title and Summary Additional Formats
Toggle Summary Alnylam and Arrowhead Form Collaboration and Licensing Agreement
– Arrowhead Receives License from Alnylam to Develop RNAi Therapeutic Toward Hepatitis B Virus (HBV) – – Alnylam Gains Access to Arrowhead's Dynamic Polyconjugate (DPC) Delivery Technology for "Alnylam 5x15" Target –
View HTML
Toggle Summary Amgen and Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations View HTML
Toggle Summary Arrowhead Acquires Novartis' RNAi Research and Development Portfolio
- Conference Call Today at 8:30 a.m. EST PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the acquisition of Novartis' entire RNAi research and development portfolio and associated
View HTML
Toggle Summary Arrowhead Added to NASDAQ Biotechnology Index®
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Research Corporation ( NASDAQ : ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has been selected for addition to the NASDAQ Biotechnology Index ( NASDAQ : NBI) as part of the annual re-ranking which
View HTML
Toggle Summary Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 8, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced Phase 2 clinical data on a double combination of JNJ-3989 (formerly ARO-HBV) and a nucleos(t)ide analog (NA), and the first clinical data on a triple combination of JNJ-3989, JNJ-6379,
View HTML
Toggle Summary Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 28, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of Phase 2 clinical data from the AROHBV1001 phase 1/2 study on a double combination of JNJ-3989 (formerly ARO-HBV) and a nucleos(t)ide analog (NA) with collaborator
View HTML
Toggle Summary Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted Therapeutics
Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted Therapeutics PASADENA, Calif. — December 18, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it has signed a research collaboration and license
View HTML
Toggle Summary Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B
PASADENA, Calif. & HOPKINTON, Mass. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. ( NASDAQ : ARWR) and Spring Bank Pharmaceuticals, Inc. ( NASDAQ : SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory
View HTML
Toggle Summary Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Fibrosis regression observed in 50% of patients receiving fazirsiran Median reductions of 94% of Z-AAT accumulation in the liver and mean reduction of 68% in histologic globule burden Treatment emergent adverse events were generally well balanced between fazirsiran and placebo groups Results
View HTML
Toggle Summary Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 15, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced ARO-DUX4 as Arrowhead’s first muscle targeted investigational RNAi therapeutic candidate to utilize its proprietary Targeted RNAi Molecule (TRIM TM ) platform.
View HTML